Subscribe To
BAYRY / Bayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'
BAYRY News
By Reuters
October 31, 2023
Bayer ordered to pay $332 mln in Roundup cancer trial -Law.com
A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's Roundup weed killer, and o more_horizontal
By Zacks Investment Research
October 17, 2023
New Strong Sell Stocks for October 17th
BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023. more_horizontal
By Yahoo Finance
October 15, 2023
Gene therapy, Parkinson's disease, and food science: Bayer U.S. discusses the latest technology
Most Americans know Bayer (BAYN.DE) for its over-the-counter medicines like Aleve and Claritin. But that's not all the company does. more_horizontal
By Zacks Investment Research
October 6, 2023
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies. more_horizontal
By Market Watch
September 12, 2023
Key drug in Sudafed, Dayquil and many other decongestants doesn't relieve congestion: FDA
WASHINGTON (AP) — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, accor more_horizontal
By Reuters
August 28, 2023
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an ea more_horizontal
By Seeking Alpha
August 22, 2023
Bayer: Still A Strong Buy Despite Lowered Guidance
Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to strug more_horizontal
By Seeking Alpha
August 8, 2023
Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript
Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill more_horizontal